Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Change in Account Payables: 2009-2025

Historic Change in Account Payables for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $1.0 million.

  • Lifecore Biomedical's Change in Account Payables rose 150.70% to $1.0 million in Q2 2025 from the same period last year, while for May 2025 it was -$1.7 million, marking a year-over-year increase of 74.99%. This contributed to the annual value of -$1.7 million for FY2025, which is 74.99% up from last year.
  • Latest data reveals that Lifecore Biomedical reported Change in Account Payables of $1.0 million as of Q2 2025, which was up 129.79% from -$3.5 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Change in Account Payables ranged from a high of $13.7 million in Q4 2021 and a low of -$12.4 million during Q2 2021.
  • Moreover, its 3-year median value for Change in Account Payables was -$367,500 (2023), whereas its average is -$401,700.
  • Its Change in Account Payables has fluctuated over the past 5 years, first soared by 212.34% in 2023, then slumped by 4,708.47% in 2024.
  • Lifecore Biomedical's Change in Account Payables (Quarterly) stood at $13.7 million in 2021, then decreased by 18.67% to $11.1 million in 2022, then slumped by 100.53% to -$59,000 in 2023, then crashed by 4,708.47% to -$2.8 million in 2024, then skyrocketed by 150.70% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q2 2025, -$3.5 million for Q1 2025, and -$2.8 million during Q4 2024.